NeoGenomics Company Profile (NASDAQ:NEO)

About NeoGenomics

NeoGenomics logoNeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. Its Laboratory Testing segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. The Company offers testing services, which includes Cytogenetics testing, which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing, which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing, which is a way to measure the characteristics of cell populations, and immunohistochemistry (IHC), and digital imaging, which is a process of localizing proteins in cells of a tissue section and relies on the principle of antibodies binding specifically to antigens in biological tissues.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NEO
  • CUSIP:
Key Metrics:
  • Previous Close: $8.07
  • 50 Day Moving Average: $8.25
  • 200 Day Moving Average: $8.38
  • 52-Week Range: $6.06 - $9.88
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 26.90
  • P/E Growth: 2.15
  • Market Cap: $655.38M
  • Outstanding Shares: 78,489,000
  • Beta: 0.92
Profitability:
  • Net Margins: -3.10%
  • Return on Equity: 3.56%
  • Return on Assets: 2.05%
Debt:
  • Debt-to-Equity Ratio: 0.29%
  • Current Ratio: 2.62%
  • Quick Ratio: 2.45%
Additional Links:
Companies Related to NeoGenomics:

Analyst Ratings

Consensus Ratings for NeoGenomics (NASDAQ:NEO) (?)
Ratings Breakdown: 1 Sell Rating, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $10.67 (32.18% upside)

Analysts' Ratings History for NeoGenomics (NASDAQ:NEO)
Show:
DateFirmActionRatingPrice TargetDetails
2/22/2017Cantor FitzgeraldSet Price TargetBuy$11.00View Rating Details
11/16/2016Axiom SecuritiesReiterated RatingHold -> SellView Rating Details
10/27/2016BTIG ResearchUpgradeNeutral -> Buy$10.00View Rating Details
10/3/2016First AnalysisInitiated CoverageOverweight$11.00View Rating Details
9/8/2016Raymond James Financial, Inc.Initiated CoverageOutperform$10.00View Rating Details
7/27/2016Benchmark Co.Boost Price TargetBuy$10.00 -> $12.00View Rating Details
7/9/2016Craig HallumReiterated RatingBuyView Rating Details
5/11/2016Roth CapitalInitiated CoverageBuy$10.00View Rating Details
1/7/2016Janney Montgomery ScottInitiated CoverageBuy$11.00View Rating Details
10/26/2015William BlairReiterated RatingBuyView Rating Details
(Data available from 3/1/2015 forward)

Earnings

Earnings History for NeoGenomics (NASDAQ:NEO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/25/2017        
2/22/2017Q416$0.03$0.05$61.83 million$60.50 millionViewListenView Earnings Details
10/26/2016Q316$0.03$0.04$61.00 million$60.76 millionViewListenView Earnings Details
7/26/2016Q216$0.03$0.04$61.07 million$63.10 millionViewListenView Earnings Details
4/27/2016Q116($0.07)$0.03$57.00 million$59.70 millionViewListenView Earnings Details
3/1/2016Q415$0.02($0.03)$26.46 million$27.30 millionViewN/AView Earnings Details
4/28/2015Q115($0.02)($0.01)$23.36 million$23.00 millionViewN/AView Earnings Details
2/24/2015Q414$0.01$0.02$24.30 million$25.00 millionViewN/AView Earnings Details
10/30/2014Q314($0.01)($0.01)$22.43 million$23.20 millionViewN/AView Earnings Details
7/17/2014Q214$0.01$0.01$19.84 million$20.70 millionViewN/AView Earnings Details
2/19/2014Q413$0.02$0.04$17.80 million$18.30 millionViewN/AView Earnings Details
10/23/2013Q313$0.01$0.02$16.84 million$16.90 millionViewN/AView Earnings Details
7/31/2013Q2 2013$0.01$16.20 million$15.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for NeoGenomics (NASDAQ:NEO)
Current Year EPS Consensus Estimate: $0.19 EPS
Next Year EPS Consensus Estimate: $0.30 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.01)($0.01)($0.01)
Q2 20161$0.01$0.01$0.01
Q3 20161$0.04$0.04$0.04
Q4 20161$0.05$0.05$0.05
(Data provided by Zacks Investment Research)

Dividends

Dividend History for NeoGenomics (NASDAQ:NEO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for NeoGenomics (NASDAQ:NEO)
Insider Ownership Percentage: 12.20%
Institutional Ownership Percentage: 79.69%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/23/2016Maher AlbitarInsiderSell2,800$8.40$23,520.00View SEC Filing  
9/20/2016Maher AlbitarInsiderSell105,300$8.20$863,460.00View SEC Filing  
9/12/2016Maher AlbitarInsiderSell60,075$8.23$494,417.25View SEC Filing  
8/19/2016Maher AlbitarInsiderSell370,000$8.23$3,045,100.00View SEC Filing  
5/27/2016Oort Douglas M VanCEOSell481,387$8.73$4,202,508.51View SEC Filing  
5/18/2016Steven A RossInsiderSell18,000$8.50$153,000.00View SEC Filing  
5/9/2016Steven A RossInsiderSell15,000$8.22$123,300.00View SEC Filing  
5/2/2016Steven C JonesVPSell177,745$8.21$1,459,286.45View SEC Filing  
4/29/2016Steven A RossInsiderSell112,500$8.11$912,375.00View SEC Filing  
3/11/2016George CardozaCFOSell32,000$6.83$218,560.00View SEC Filing  
3/9/2016Oort Douglas M VanCEOSell450,000$7.10$3,195,000.00View SEC Filing  
3/3/2016Alison L HannahDirectorBuy10,000$6.90$69,000.00View SEC Filing  
12/7/2015Lynn A TetraultDirectorBuy3,500$7.72$27,020.00View SEC Filing  
12/3/2015Robert J ShovlinCOOBuy6,550$7.75$50,762.50View SEC Filing  
11/27/2015Steven C JonesVPSell385,000$8.09$3,114,650.00View SEC Filing  
11/2/2015Bruce K CrowtherDirectorBuy6,400$7.81$49,984.00View SEC Filing  
12/19/2014Robert H HorelVPSell32,389$4.21$136,357.69View SEC Filing  
12/18/2014Robert H HorelVPSell62,893$4.20$264,150.60View SEC Filing  
12/4/2014Michael T DentDirectorSell11,800$4.50$53,100.00View SEC Filing  
11/26/2014George CardozaCFOSell60,000$4.28$256,800.00View SEC Filing  
11/21/2014Michael T DentDirectorSell33,200$4.51$149,732.00View SEC Filing  
5/22/2014Robert P GaspariniInsiderSell100,000$3.49$349,000.00View SEC Filing  
5/19/2014Robert GaspariniInsiderSell10,000$3.65$36,500.00View SEC Filing  
3/28/2014Maher AlbitarInsiderBuy14,492$3.51$50,866.92View SEC Filing  
3/5/2014Michael T DentDirectorSell300,000$3.00$900,000.00View SEC Filing  
12/11/2013Robert P GaspariniInsiderSell20,100$3.70$74,370.00View SEC Filing  
12/9/2013George CardozaCFOSell20,000$3.66$73,200.00View SEC Filing  
12/5/2013Robert P GaspariniInsiderSell32,996$3.67$121,095.32View SEC Filing  
12/3/2013Robert P GaspariniInsiderSell32,146$3.67$117,975.82View SEC Filing  
11/25/2013Steven C JonesVPSell112,969$3.58$404,429.02View SEC Filing  
4/30/2013Steven C JonesDirectorSell100,000$3.71$371,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for NeoGenomics (NASDAQ:NEO)
DateHeadline
News IconNeoGenomics Inc NEO Medical Equipment Deals and Alliances Profile [Updated: 24012017] Prices from USD $250 (NASDAQ:NEO)
www.bioportfolio.com - March 1 at 10:40 AM
News IconTrading Insight: Taking a Look at Levels for Neogenomics Inc (NEO) - Davidson Register (NASDAQ:NEO)
davidsonregister.com - February 25 at 8:07 AM
4-traders.com logoNEOGENOMICS INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) (NASDAQ:NEO)
www.4-traders.com - February 24 at 7:51 PM
capitalcube.com logoNeoGenomics, Inc. :NEO-US: Earnings Analysis: Q4, 2016 By the Numbers : February 23, 2017 (NASDAQ:NEO)
us.rd.yahoo.com - February 23 at 11:50 PM
capitalcube.com logoNeoGenomics, Inc. :NEO-US: Earnings Analysis: 2016 By the Numbers : February 23, 2017 (NASDAQ:NEO)
us.rd.yahoo.com - February 23 at 11:50 PM
News IconStock Watch for Neogenomics Inc (NEO) - Baxter Review (NASDAQ:NEO)
baxternewsreview.com - February 23 at 6:50 PM
News IconTag: NeoGenomics Inc. - StockNewsUnion (NASDAQ:NEO)
stocknewsunion.com - February 23 at 6:50 PM
einnews.com logoGlobal Cancer/Tumor Profiling Market Analysis and Forecast 2022 by Size, Share and Growth Rate (NASDAQ:NEO)
world.einnews.com - February 23 at 8:52 AM
4-traders.com logoNEOGENOMICS, INC. (NASDAQ:NEO) Files An 8-K Results of Operations and Financial Condition (NASDAQ:NEO)
www.4-traders.com - February 23 at 12:28 AM
finance.yahoo.com logoEdited Transcript of NEO earnings conference call or presentation 22-Feb-17 4:00pm GMT (NASDAQ:NEO)
finance.yahoo.com - February 23 at 12:27 AM
reuters.com logoBRIEF-NeoGenomics Q4 GAAP loss per share $0.18 (NASDAQ:NEO)
www.reuters.com - February 22 at 6:55 PM
4-traders.com logoNeoGenomics : hits bump in the road, sees smoother road ahead (NASDAQ:NEO)
www.4-traders.com - February 22 at 6:55 PM
us.rd.yahoo.com logoNeoGenomics Reports 122% Revenue Growth to $60.5 Million and 11% Reduction in Average Cost per Test in the Fourth Quarter of 2016 (NASDAQ:NEO)
us.rd.yahoo.com - February 22 at 6:54 PM
us.rd.yahoo.com logo7:05 am NeoGenomics beats by $0.02, misses on revs; guides FY17 EPS in-line, revs in-line (NASDAQ:NEO)
us.rd.yahoo.com - February 22 at 6:54 PM
biz.yahoo.com logoNEOGENOMICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:NEO)
biz.yahoo.com - February 22 at 6:54 PM
finance.yahoo.com logoNeoGenomics Reports 122% Revenue Growth to $60.5 Million and 11% Reduction in Average Cost per Test in the ... - Yahoo Finance (NASDAQ:NEO)
finance.yahoo.com - February 22 at 8:46 AM
News IconNeoGenomics, Inc. (NASDAQ:NEO) To Report $0.01 According to Consensus - Winfield Review (NASDAQ:NEO)
winfieldreview.com - February 22 at 8:46 AM
seekingalpha.com logoNeoGenomics reports Q4 and FY16 results; updates guidance - Seeking Alpha (NASDAQ:NEO)
seekingalpha.com - February 22 at 8:46 AM
sg.finance.yahoo.com logoNeoGenomics reports 4Q loss (NASDAQ:NEO)
sg.finance.yahoo.com - February 22 at 8:46 AM
investornewswire.com logoConsensus Rating Of NeoGenomics, Inc. (NASDAQ:NEO) Set At 1.13 - Investor Newswire (NASDAQ:NEO)
www.investornewswire.com - February 21 at 6:07 PM
News IconStock Levels in Review for Neogenomics Inc (NEO) - Davidson Register (NASDAQ:NEO)
davidsonregister.com - February 21 at 6:06 PM
News IconInvestor Network Invites You to the NeoGenomics Fourth Quarter and Full Year 2016 Earnings Conference Call and ... - Military Technologies (NASDAQ:NEO)
www.military-technologies.net - February 21 at 6:06 PM
finance.yahoo.com logoInvestor Network Invites You to the NeoGenomics Fourth Quarter and Full Year 2016 Earnings Conference Call and Webcast Live on Wednesday, February 22, 2017 (NASDAQ:NEO)
finance.yahoo.com - February 21 at 6:06 PM
nasdaq.com logoFirst Light Asset Management, LLC Buys Immunomedics, NeoGenomics, Shire PLC, Sells BioScrip, ... - Nasdaq (NASDAQ:NEO)
www.nasdaq.com - February 18 at 6:45 AM
News IconAre Analysts Optimistic About Where NeoGenomics, Inc. (NASDAQ:NEO) is Heading? - Winfield Review (NASDAQ:NEO)
winfieldreview.com - February 17 at 3:22 PM
News IconFollowing the Numbers on Shares of NeoGenomics, Inc. (NASDAQ ... - Benton Bulletin (NASDAQ:NEO)
bentonbulletin.com - February 17 at 8:06 AM
gurufocus.com logoFeb 16, 2017 - First Light Asset Management, LLC Buys ... - GuruFocus.com (NASDAQ:NEO)
www.gurufocus.com - February 17 at 8:06 AM
News IconFollowing the Numbers on Shares of NeoGenomics, Inc. (NASDAQ:NEO) - Benton Bulletin (NASDAQ:NEO)
bentonbulletin.com - February 16 at 6:22 PM
biz.yahoo.com logoNEOGENOMICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits (NASDAQ:NEO)
biz.yahoo.com - February 16 at 6:22 PM
News IconWatching Shares of NeoGenomics, Inc. (NASDAQ:NEO) - Rives Journal (NASDAQ:NEO)
rivesjournal.com - February 14 at 9:26 PM
realistinvestor.com logoNeoGenomics, Inc. (NASDAQ:NEO) EPS Projection At $0.07 - RealistInvestor.com (NASDAQ:NEO)
www.realistinvestor.com - February 14 at 9:26 PM
realistinvestor.com logoThe Growth Forecast For NeoGenomics, Inc. (NASDAQ:NEO) - RealistInvestor.com (NASDAQ:NEO)
www.realistinvestor.com - February 12 at 11:41 PM
uk.finance.yahoo.com logoNeoGenomics Schedules its Q4 and Full Year 2016 Earnings … (NASDAQ:NEO)
uk.finance.yahoo.com - February 8 at 7:41 PM
finance.yahoo.com logoNeoGenomics Schedules its Q4 and Full Year 2016 Earnings Release for February 22, 2017 (NASDAQ:NEO)
finance.yahoo.com - February 8 at 7:41 PM
streetinsider.com logoForm 4 NEOGENOMICS INC For: Feb 02 Filed by: VAN OORT DOUGLAS M - StreetInsider.com (NASDAQ:NEO)
www.streetinsider.com - February 7 at 3:26 PM
News IconPerkins Capital Management Inc Cuts Position in NeoGenomics ... - Highland Mirror (NASDAQ:NEO)
www.highlandmirror.com - February 7 at 3:26 PM
newsmaker.com.au logoGrowth Predicted for Pathogen Identification and Treatment Market : 2016 - 2022 (NASDAQ:NEO)
www.newsmaker.com.au - February 6 at 9:37 AM
realistinvestor.com logoNeoGenomics, Inc. (NASDAQ:NEO) EPS Projection At $0.08 - RealistInvestor.com (NASDAQ:NEO)
www.realistinvestor.com - February 2 at 12:54 AM
News IconCancer/Tumor Profiling Global Market by Product & Data Validation, Analysis and Forecast 2022 (NASDAQ:NEO)
empowerednews.net - January 28 at 11:56 PM
News IconTicker Tracker: Looking at Neogenomics Inc. (NEO) - Rives Journal (NASDAQ:NEO)
rivesjournal.com - January 28 at 6:53 PM
News IconEquity Research Analysts Peer Into Their Crystal Ball For Neogenomics, Inc. (NASDAQ:NEO) - Aiken Advocate (NASDAQ:NEO)
aikenadvocate.com - January 28 at 3:00 AM
News IconEarnings Take Center Stage; Analysts Weighing in on NeoGenomics, Inc. (NASDAQ:NEO) - Aiken Advocate (NASDAQ:NEO)
aikenadvocate.com - January 27 at 5:13 AM
News IconTrading Spotlight: Zooming in on Shares of Neogenomics Inc. (NEO) - Sherwood Daily (NASDAQ:NEO)
sherwooddaily.com - January 26 at 11:14 PM
News IconEarnings in Full Force, Analysts Take Aim at NeoGenomics, Inc. (NASDAQ:NEO) - Wall Street Beacon (NASDAQ:NEO)
wsbeacon.com - January 26 at 11:14 PM
News IconCancer/Tumor Profiling Market by Product & Data Validation, Analysis and Forecast 2022 (NASDAQ:NEO)
www.emailwire.com - January 26 at 1:59 AM
News IconStock Spotlight: Zooming in on Shares of Neogenomics, Inc. (NASDAQ:NEO) - The Tribune (NASDAQ:NEO)
lakecitytribune.com - January 25 at 8:57 PM
News IconEquity Rundown: RSI and CCI Check on Neogenomics Inc. (NEO ... - Sherwood Daily (NASDAQ:NEO)
sherwooddaily.com - January 25 at 5:34 AM
realistinvestor.com logoEPS Projection Of NeoGenomics, Inc. (NASDAQ:NEO) At $0.08 - RealistInvestor.com (NASDAQ:NEO)
www.realistinvestor.com - January 25 at 5:34 AM
openpr.com logoPathogen Identification and Treatment Market Is Expected to Witness a Steady Growth By 2022 - Says PMR (NASDAQ:NEO)
www.openpr.com - January 24 at 7:31 PM
News IconMA Levels in Review for Neogenomics Inc. (NEO) - Rives Journal (NASDAQ:NEO)
rivesjournal.com - January 21 at 12:34 AM

Social

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

Where is NeoGenomics' stock going? Where will NeoGenomics' stock price be in 2017?

8 equities research analysts have issued 12 month target prices for NeoGenomics' stock. Their predictions range from $10.00 to $12.00. On average, they anticipate NeoGenomics' share price to reach $10.67 in the next twelve months.

When will NeoGenomics announce their earnings?

NeoGenomics is scheduled to release their next quarterly earnings announcement on Tuesday, April, 25th 2017.

Who owns NeoGenomics stock?

NeoGenomics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Artisan Partners Limited Partnership (3.28%), First Light Asset Management LLC (3.28%), Russell Investments Group Ltd. (1.94%), Cortina Asset Management LLC (1.56%), Castleark Management LLC (1.24%) and State Street Corp (1.17%). Company insiders that own NeoGenomics stock include Alison L Hannah, Bruce K Crowther, George Cardoza, Lynn A Tetrault, Maher Albitar, Oort Douglas M Van, Robert J Shovlin, Steven A Ross and Steven C Jones.

Who sold NeoGenomics stock? Who is selling NeoGenomics stock?

NeoGenomics' stock was sold by a variety of institutional investors in the last quarter, including Allianz Asset Management AG, Artisan Partners Limited Partnership, Nicholas Investment Partners LP, Royce & Associates LP, Kopp Investment Advisors LLC, Terril Brothers Inc., Bard Associates Inc. and AQR Capital Management LLC. Company insiders that have sold NeoGenomics stock in the last year include George Cardoza, Maher Albitar, Oort Douglas M Van, Steven A Ross and Steven C Jones.

Who bought NeoGenomics stock? Who is buying NeoGenomics stock?

NeoGenomics' stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., First Light Asset Management LLC, William Blair Investment Management LLC, Cortina Asset Management LLC, Millrace Asset Group Inc., Dimensional Fund Advisors LP, Axiom International Investors LLC DE and Century Capital Management LLC. Company insiders that have bought NeoGenomics stock in the last two years include Alison L Hannah, Bruce K Crowther, Lynn A Tetrault and Robert J Shovlin.

How do I buy NeoGenomics stock?

Shares of NeoGenomics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of NeoGenomics stock cost?

One share of NeoGenomics stock can currently be purchased for approximately $8.07.

NeoGenomics (NASDAQ:NEO) Chart for Wednesday, March, 1, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Earnings History Chart

Earnings by Quarter for NeoGenomics (NASDAQ:NEO)

Dividend History Chart

Dividend Payments by Quarter for NeoGenomics (NASDAQ:NEO)

Last Updated on 3/1/2017 by MarketBeat.com Staff